Second Genome has entered into an agreement with Pfizer to conduct microbiome research in a large observational study to gain new insights into obesity and metabolic disease. The study will evaluate numerous clinical factors and the microbiome in a select cohort of approximately 900 individuals with varying metabolic phenotypes.   Research suggests that microbiome is central to metabolic processes and changes in the composition of gut microbes appear to be linked to metabolic conditions such as ...